PPAR-γ与纤维化疾病关系研究进展  

Research progress in the correlation between peroxisome proliferator-activated receptor gamma and fibrotic diseases

作　　者：雷蕾[1] 陈俊杰[1] 岑瑛[1] 

机构地区：[1]四川大学华西医院烧伤整形科,四川成都610041

出　　处：《西部医学》2017年第3期437-440,共4页Medical Journal of West China

基　　金：国家自然科学基金(81101180;81171822;81571915);四川省科技厅应用基础项目(2016JY0153)

摘　　要：纤维化疾病是临床上常见的疾病,至今仍是一个治疗难题。近年来的研究发现,过氧化物酶体增殖物激活受体(PPARs)中PPAR-γ亚型的活化或激动剂在器官纤维化的发生过程中有调节作用,可减缓纤维化进程。本文就PPAR-γ与肝、肾、肺、心肌、眼及皮肤等器官纤维化发病关系的研究现状与进展做一综述。Fibrotic disease is a common clinical disease and the treatment is still a problem. Peroxisome proliferator activated receptor-γ（PPAR-γ） is a subtype of peroxisome proliferator-aetivated receptors（PPARs）. Recent studies have found that PPAR-γ＇s activators or agonists have a moderating effect in the occurrence of organ fibrosis, it may slow fibrotic process. In this article, we reviewed medical literatures related to PPAR-γ and fibrotic diseases in liver, kidney, lung, heart, eyes, skin and other organ.

关 键 词：PPAR-Γ 肝纤维化 肾纤维化 肺纤维化 皮肤纤维化 

分 类 号：R59[医药卫生—内科学]